217 related articles for article (PubMed ID: 20937175)
1. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
Kunst H; Khan KS
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
[TBL] [Abstract][Full Text] [Related]
3. Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Jonas DE; Riley SR; Lee LC; Coffey CP; Wang SH; Asher GN; Berry AM; Williams N; Balio C; Voisin CE; Kahwati LC
JAMA; 2023 May; 329(17):1495-1509. PubMed ID: 37129650
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Zenner D; Beer N; Harris RJ; Lipman MC; Stagg HR; van der Werf MJ
Ann Intern Med; 2017 Aug; 167(4):248-255. PubMed ID: 28761946
[TBL] [Abstract][Full Text] [Related]
6. Treatment of latent tuberculosis infection: a network meta-analysis.
Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
[TBL] [Abstract][Full Text] [Related]
7. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
Bliven EE; Podewils LJ
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.
Hosford JD; von Fricken ME; Lauzardo M; Chang M; Dai Y; Lyon JA; Shuster J; Fennelly KP
Tuberculosis (Edinb); 2015 Mar; 95(2):112-22. PubMed ID: 25595441
[TBL] [Abstract][Full Text] [Related]
9. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults.
Devrim I; Olukman O; Can D; Dizdarer C
Chest; 2010 Mar; 137(3):737-8. PubMed ID: 20202962
[No Abstract] [Full Text] [Related]
12. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
[TBL] [Abstract][Full Text] [Related]
13. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.
Ronald LA; FitzGerald JM; Bartlett-Esquilant G; Schwartzman K; Benedetti A; Boivin JF; Menzies D
Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31980498
[TBL] [Abstract][Full Text] [Related]
14. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
15. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
[TBL] [Abstract][Full Text] [Related]
17. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
18. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
19. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
20. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]